- Home
- RNR vs ICLR Comparison
RNR vs ICLR Comparison
Compare RNR & ICLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNR
- ICLR
- Stock Information
- Founded
- RNR 1993
- ICLR 1990
- Country
- RNR Bermuda
- ICLR Ireland
- Employees
- RNR N/A
- ICLR N/A
- Industry
- RNR Property-Casualty Insurers
- ICLR Biotechnology: Commercial Physical & Biological Resarch
- Sector
- RNR Finance
- ICLR Health Care
- Exchange
- RNR Nasdaq
- ICLR Nasdaq
- Market Cap
- RNR 11.8B
- ICLR 11.6B
- IPO Year
- RNR 1995
- ICLR 1998
- Fundamental
- Price
- RNR $236.00
- ICLR $143.54
- Analyst Decision
- RNR Buy
- ICLR Buy
- Analyst Count
- RNR 11
- ICLR 12
- Target Price
- RNR $287.40
- ICLR $187.82
- AVG Volume (30 Days)
- RNR 462.5K
- ICLR 1.2M
- Earning Date
- RNR 07-23-2025
- ICLR 07-23-2025
- Dividend Yield
- RNR 0.68%
- ICLR N/A
- EPS Growth
- RNR N/A
- ICLR 11.53
- EPS
- RNR 31.81
- ICLR 9.19
- Revenue
- RNR $12,613,932,000.00
- ICLR $8,192,621,999.00
- Revenue This Year
- RNR N/A
- ICLR N/A
- Revenue Next Year
- RNR $1.24
- ICLR $1.69
- P/E Ratio
- RNR $7.44
- ICLR $15.98
- Revenue Growth
- RNR 31.51
- ICLR N/A
- 52 Week Low
- RNR $210.51
- ICLR $125.10
- 52 Week High
- RNR $300.00
- ICLR $342.55
- Technical
- Relative Strength Index (RSI)
- RNR 42.56
- ICLR 45.87
- Support Level
- RNR $235.94
- ICLR $142.16
- Resistance Level
- RNR $239.92
- ICLR $153.62
- Average True Range (ATR)
- RNR 4.03
- ICLR 5.51
- MACD
- RNR -0.27
- ICLR -0.91
- Stochastic Oscillator
- RNR 15.87
- ICLR 10.04
About RNR RenaissanceRe Holdings Ltd.
RenaissanceRe Holdings Ltd provides reinsurance and insurance solutions and related services. The company's core products include property, casualty and specialty reinsurance. Revenue is derived from three sources: net premiums earned from the insurance and insurance products sold; net investment income from the investment of capital funds and cash; and other income from the company's joint ventures, advisory services, and other items. The reportable segments of the company are the Property segment which includes catastrophe and other property reinsurance, and the Casualty and Specialty segment which is comprised of casualty and specialty reinsurance. It derives a majority of its revenue from the Casualty and specialty segment.
About ICLR ICON plc
Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.